{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:24:01Z","timestamp":1789773841989,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF, No. 2021R1C1C1005930"],"award-info":[{"award-number":["NRF, No. 2021R1C1C1005930"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background and purpose<\/jats:title>\n            <jats:p>This study aimed to evaluate the impact of pelvic radiation therapy (RT) on the occurrence of severe radiation-induced lymphopenia (SRIL) and identify its clinical and dosimetric predictors using voxel-wise analysis. Understanding these impacts is crucial for improving patient outcomes and optimizing treatment protocols in radiation oncology.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and methods<\/jats:title>\n            <jats:p>A retrospective analysis was conducted on 122 patients who underwent pelvic RT. Absolute lymphocyte counts (ALC) were measured before treatment and within one month of RT initiation. Patients were classified into SRIL and non-SRIL groups on the basis of their lowest recorded ALC during treatment. The associations between SRIL and clinical\/dosimetric parameters were assessed via univariable (UVA) and multivariate (MVA) analysis. The influence of regionally detailed dose was assessed by voxel-based analysis (VBA) on spatially normalized 3D dose maps and CT images, focusing on the sacrum, femoral heads, and pelvic bones.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>SRIL was associated with clinical and dosimetric factors. The baseline ALC was the most significant clinical predictor, with a lower baseline ALC increasing SRIL risk (OR\u2009=\u20090.996, <jats:italic>p<\/jats:italic>\u2009=\u20090.001). VBA further revealed localized highly related regional dose patterns, with 92.17% of the left femoral head and 91.32% of the right femoral head showing significant SRIL associations, whereas the associations were significantly lower in the sacrum (10.39%) and pelvic bones (left: 30.01%, right: 31.52%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This study identified key clinical and dosimetric factors influencing SRIL in patients undergoing pelvic radiotherapy. Baseline ALC was the most significant clinical factor, and VBA showed that regional dose pattern changes within the femoral head were significantly associated with SRIL.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical trial number<\/jats:title>\n            <jats:p>Not applicable.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13014-025-02652-5","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T19:46:32Z","timestamp":1748979992000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Exploring the impact of pelvic radiotherapy dose distribution on lymphocyte counts: a voxel-based analysis"],"prefix":"10.1186","volume":"20","author":[{"given":"Sanghyeok","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seohan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangseok","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu-Hye","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wonmo","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"2652_CR1","doi-asserted-by":"crossref","unstructured":"Wang, Y., V. Probin, and D. Zhou, Cancer therapy-induced residual bone marrow injury-Mechanisms of induction and implication for therapy. Curr Cancer Ther Rev, 2006;2(3): p. 271\u2013279.","DOI":"10.2174\/157339406777934717"},{"key":"2652_CR2","doi-asserted-by":"crossref","unstructured":"Belka, C., et al., Radiation induced CNS toxicity\u2013molecular and cellular mechanisms. Br J Cancer, 2001;85(9):1233-9.","DOI":"10.1054\/bjoc.2001.2100"},{"key":"2652_CR3","doi-asserted-by":"crossref","unstructured":"Venkatesulu, B.P., et al., A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors. Crit Rev Oncol Hematol, 2018;123:42\u201351.","DOI":"10.1016\/j.critrevonc.2018.01.003"},{"key":"2652_CR4","doi-asserted-by":"crossref","unstructured":"Prades-Sagarra, E., A. Yaromina, and L.J. Dubois, Understanding the impact of radiation-induced lymphopenia: Preclinical and clinical research perspectives. Clin Transl Radiat Oncol, 2024;49:100852.","DOI":"10.1016\/j.ctro.2024.100852"},{"key":"2652_CR5","doi-asserted-by":"crossref","unstructured":"Tang, C., et al., Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. Int J Radiat Oncol Biol Phys, 2014;89(5):1084\u20131091.","DOI":"10.1016\/j.ijrobp.2014.04.025"},{"key":"2652_CR6","doi-asserted-by":"crossref","unstructured":"Campian, J.L., et al., Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer. Cancer Invest, 2013.;31(3):183-8.","DOI":"10.3109\/07357907.2013.767342"},{"key":"2652_CR7","doi-asserted-by":"crossref","unstructured":"Stefanoudakis, D., et al., Immunotherapy in Cervical and Endometrial Cancer: Current Landscape and Future Directions. Life, 2024;14(3):344.","DOI":"10.3390\/life14030344"},{"key":"2652_CR8","doi-asserted-by":"crossref","unstructured":"M\u00e9n\u00e9trier-Caux, C., et al., Lymphopenia in cancer patients and its effects on response to immunotherapy: an opportunity for combination with cytokines? Journal for immunotherapy of cancer, 2019;7(1):1\u201315.","DOI":"10.1186\/s40425-019-0549-5"},{"key":"2652_CR9","doi-asserted-by":"crossref","unstructured":"Sini, C., et al., Dose\u2013volume effects for pelvic bone marrow in predicting hematological toxicity in prostate cancer radiotherapy with pelvic node irradiation. Radiotherapy and Oncology, 2016;118(1):79\u201384.","DOI":"10.1016\/j.radonc.2015.11.020"},{"key":"2652_CR10","doi-asserted-by":"crossref","unstructured":"Iorio, G.C., et al., The Impact of Pelvic Nodal Radiotherapy on Hematologic Toxicity: A Systematic Review with Focus on Leukopenia, Lymphopenia and Future Perspectives in Prostate Cancer Treatment. Critical Reviews in Oncology\/Hematology, 2021;168:103497\u2013103497.","DOI":"10.1016\/j.critrevonc.2021.103497"},{"key":"2652_CR11","doi-asserted-by":"crossref","unstructured":"Huang, J., et al., Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial. Radiat Oncol, 2020;15(1):180.","DOI":"10.1186\/s13014-020-01606-3"},{"key":"2652_CR12","doi-asserted-by":"crossref","unstructured":"Rose, B.S., et al., Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys, 2011;79(3):800-7.","DOI":"10.1016\/j.ijrobp.2009.11.010"},{"key":"2652_CR13","doi-asserted-by":"crossref","unstructured":"Acosta, O., et al., Voxel-based population analysis for correlating local dose and rectal toxicity in prostate cancer radiotherapy. Phys Med Biol, 2013;58(8):2581-95.","DOI":"10.1088\/0031-9155\/58\/8\/2581"},{"key":"2652_CR14","doi-asserted-by":"crossref","unstructured":"14. Palma, G., S. Monti, and L. Cella, Voxel-based analysis in radiation oncology: A methodological cookbook. Phys Med, 2020;69:192\u2013204.","DOI":"10.1016\/j.ejmp.2019.12.013"},{"key":"2652_CR15","doi-asserted-by":"crossref","unstructured":"Palma, G., L. Cella, and S. Monti, Technical note: MAMBA\u2014Multi-pAradigM voxel-Based Analysis: A computational cookbot. Medical Physics, 2023;50(4):2317\u20132322.","DOI":"10.1002\/mp.16260"},{"key":"2652_CR16","doi-asserted-by":"crossref","unstructured":"McWilliam, A., et al., Voxel-based analysis: Roadmap for clinical translation. Radiotherapy and Oncology, 2023;188:109868.","DOI":"10.1016\/j.radonc.2023.109868"},{"key":"2652_CR17","doi-asserted-by":"crossref","unstructured":"Mell, L.K., et al., Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys, 2006;66(5):1356-65.","DOI":"10.1016\/j.ijrobp.2006.03.018"},{"key":"2652_CR18","doi-asserted-by":"crossref","unstructured":"Klopp, A.H., et al., Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer. Int J Radiat Oncol Biol Phys, 2013;86(1):83\u201390.","DOI":"10.1016\/j.ijrobp.2013.01.017"},{"key":"2652_CR19","doi-asserted-by":"crossref","unstructured":"Corbeau, A., et al., Correlations between bone marrow radiation dose and hematologic toxicity in locally advanced cervical cancer patients receiving chemoradiation with cisplatin: a systematic review. Radiother Oncol, 2021;164:128\u2013137.","DOI":"10.1016\/j.radonc.2021.09.009"},{"key":"2652_CR20","unstructured":"Sharp, G.C., et al. Plastimatch: an open source software suite for radiotherapy image processing. in Proceedings of the XVI\u2019th International Conference on the use of Computers in Radiotherapy (ICCR), Amsterdam, Netherlands. 2010."},{"key":"2652_CR21","doi-asserted-by":"crossref","unstructured":"Smith, S.M. and T.E. Nichols, Threshold-free cluster enhancement: Addressing problems of smoothing, threshold dependence and localisation in cluster inference. NeuroImage, 2009;44(1):83\u201398.","DOI":"10.1016\/j.neuroimage.2008.03.061"},{"key":"2652_CR22","doi-asserted-by":"crossref","unstructured":"Hayman, J.A., et al., Distribution of Proliferating Bone Marrow in Adult Cancer Patients Determined Using FLT-PET Imaging. International Journal of Radiation Oncology*Biology*Physics, 2011;79(3):847\u2013852.","DOI":"10.1016\/j.ijrobp.2009.11.040"},{"key":"2652_CR23","doi-asserted-by":"crossref","unstructured":"Ellis, R.E., The Distribution of Active Bone Marrow in the Adult. Physics in Medicine & Biology, 1961;5(3):255.","DOI":"10.1088\/0031-9155\/5\/3\/302"},{"key":"2652_CR24","doi-asserted-by":"crossref","unstructured":"Ellis, R.E., The distribution of active bone marrow in the adult. Phys Med Biol, 1961;5:255-8.","DOI":"10.1088\/0031-9155\/5\/3\/302"},{"key":"2652_CR25","doi-asserted-by":"crossref","unstructured":"Rose, B.S., et al., Correlation between radiation dose to 18F-FDG-PET defined active bone marrow subregions and acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy. International Journal of Radiation Oncology* Biology* Physics, 2012;83(4):1185\u20131191.","DOI":"10.1016\/j.ijrobp.2011.09.048"},{"key":"2652_CR26","doi-asserted-by":"crossref","unstructured":"Li, N., et al., Association between dose-volume parameters and acute bone marrow suppression in rectal cancer patients treated with concurrent chemoradiotherapy. Oncotarget, 2017;8(54):92904\u201392913.","DOI":"10.18632\/oncotarget.21646"},{"key":"2652_CR27","doi-asserted-by":"crossref","unstructured":"Albuquerque, K., et al., Radiation-related predictors of hematologic toxicity after concurrent chemoradiation for cervical cancer and implications for bone marrow-sparing pelvic IMRT. Int J Radiat Oncol Biol Phys, 2011;79(4):1043-7.","DOI":"10.1016\/j.ijrobp.2009.12.025"},{"key":"2652_CR28","doi-asserted-by":"crossref","unstructured":"Monti, S., et al., On the interplay between dosiomics and genomics in radiation-induced lymphopenia of lung cancer patients. Radiother Oncol, 2022;167:219\u2013225.","DOI":"10.1016\/j.radonc.2021.12.038"},{"key":"2652_CR29","doi-asserted-by":"crossref","unstructured":"Vinnicombe, S.J., et al., Normal pelvic lymph nodes: evaluation with CT after bipedal lymphangiography. Radiology, 1995;194(2):349\u2013355.","DOI":"10.1148\/radiology.194.2.7824709"},{"key":"2652_CR30","doi-asserted-by":"crossref","unstructured":"Zhou, P., et al., Pelvic bone marrow sparing radiotherapy for cervical cancer: A systematic review and meta-analysis. Radiother Oncol, 2021;165:103\u2013118.","DOI":"10.1016\/j.radonc.2021.10.015"},{"key":"2652_CR31","doi-asserted-by":"crossref","unstructured":"Wahl, M., et al., Interfraction Anatomical Variability Can Lead to Significantly Increased Rectal Dose for Patients Undergoing Stereotactic Body Radiotherapy for Prostate Cancer. Technol Cancer Res Treat, 2017;16(2):178\u2013187.","DOI":"10.1177\/1533034616649495"},{"key":"2652_CR32","doi-asserted-by":"crossref","unstructured":"Gaudreault, M., et al., Assessing organ at risk position variation and its impact on delivered dose in kidney SABR.Radiat Oncol, 2022;17(1):112.","DOI":"10.1186\/s13014-022-02041-2"},{"key":"2652_CR33","doi-asserted-by":"crossref","unstructured":"Kim, S., et al., Normal Tissue Complication Probability Modeling of Severe Radiation-Induced Lymphopenia Using Blood Dose for Patients With Hepatocellular Carcinoma. International Journal of Radiation Oncology*Biology*Physics, 2024;119(3):1011\u20131020.","DOI":"10.1016\/j.ijrobp.2023.11.060"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02652-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-025-02652-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02652-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T19:46:38Z","timestamp":1748979998000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-025-02652-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2652"],"URL":"https:\/\/doi.org\/10.1186\/s13014-025-02652-5","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"assertion":[{"value":"14 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in compliance with the Declaration of Helsinki\u2013 Ethical Principles for Medical Research Involving Human Participants. This study approval from the The Catholic University of Korea, Catholic Medical Center Institutional Review Board (IRB) was obtained prior to the commencement of the study (IRB No. KC22RISI0715). All patient data used in this study were obtained with written consent from the patients or their guardians.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Dr. Sung has a research collaboration with RayMed Inc. Other authors declare no potential conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"92"}}